Raymond D. Meng

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein et al. · The Lancet Oncology · 2022 · 399 citations · Full text

γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity

Raymond D. Meng, Christopher C. Shelton, Yue-Ming Li et al. · Cancer Research · 2009 · 298 citations · Full text

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Delvys Rodríguez‐Abreu, Melissa L. Johnson, Maen Hussein et al. · Journal of Clinical Oncology · 2020 · 240 citations

Pd-l1-selected Nsclc, Immunology, Immunoediting +20

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Cristina Saura, Desamparados Roda, Susana Roselló et al. · Cancer Discovery · 2016 · 167 citations · Full text

p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-γ

Raymond D. Meng, Wafik S. El‐Deiry · Experimental Cell Research · 2001 · 130 citations

Signal Transduction, Immunology, Immune Regulation +7